Challenging the Treatment Threshold: Early Faricimab Prevents Vision Loss in nAMD – A Real-World Welsh Experience
Parinita Keshav Swarnkar, Jaskaran Singh Bhangu, Christopher Stewart, Mohammed Rifat, Sarah Khalid, Harry Winkworth, Savannah Lydia Franklin-Goddard, Mahmoud Husseiny Awad, Gwyn Samuel Williams · 2026
Read Challenging the Treatment Threshold: Early Faricimab Prevents Vision Loss in nAMD – A Real-World Welsh Experience by Parinita Keshav Swarnkar, Jaskaran Singh Bhangu, Christopher Stewart, Mohammed Rifat, Sarah Khalid, Harry Winkworth, Savannah Lydia Franklin-Goddard, Mahmoud Husseiny Awad, Gwyn Samuel Williams (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13218209.txt.
Description
Parinita Keshav Swarnkar and co-authors report a 2026 study of early drug care for a wet eye disease of old age. The disease leaks fluid at the back of the eye and can blind if care starts late. The team compared patients who began a drug called faricimab while sight was still good with those who began when sight was poor.
The Welsh centre study covered 97 patients new to care. No patient in the early group lost sight in a lasting way over 18 months. About three quarters of the late group did lose sight at each check. By the seventh shot, about two thirds of the late group had lost at least five letters on the eye chart, far above the early group.
Catalog record
| CREATOR | Parinita Keshav Swarnkar, Jaskaran Singh Bhangu, Christopher Stewart, Mohammed Rifat, Sarah Khalid, Harry Winkworth, Savannah Lydia Franklin-Goddard, Mahmoud Husseiny Awad, Gwyn Samuel Williams |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |